Overview: Friedreich's Ataxia Mutation TestIntroduction: The Friedreich's Ataxia Mutation Test detects frataxin gene mutations to diagnose Friedreich's ataxia, causing coordination loss or muscle weakness. Aligned with 2023 AAN guidelines, it uses PCR for high specificity, aiding in genetic screening. This test is critical for guiding diagnosis, management, and improving outcomes in molecular pathology for patients with suspected Friedreich's ataxia.
Other Names: Frataxin Mutation Assay, Friedreich's Ataxia Genetic Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Friedreich's ataxia testing began in the 1990s with frataxin gene discovery. PCR-based assays emerged in the 2000s, improving accuracy for mutation detection.
Purpose: Diagnoses Friedreich's ataxia, guides management, and monitors frataxin mutations in patients with coordination loss or muscle weakness.
Test Parameters: 1. Frataxin Gene Mutation
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva at any time. Report symptoms like coordination loss or muscle weakness, and list family history.
Specimen: 2-5 mL whole blood (EDTA), 1-2 buccal swabs (sterile swab), or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document coordination loss, muscle weakness, or family history of Friedreich's ataxia. Include current medications.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for genetic counseling.
Procedural Considerations: Uses PCR to detect frataxin gene mutations (e.g., GAA repeats). Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Low DNA yield or contamination can affect results. Rare mutations may require additional testing.
Clinical Significance: Positive frataxin mutations confirm Friedreich's ataxia, prompting management. Negative results may require further genetic testing.
Specialist Consultation: Consult a neurologist or geneticist for result interpretation.
Additional Supporting Tests: Neurological exam, EMG, or other genetic tests to confirm Friedreich's ataxia.
Test Limitations: False negatives may occur with rare mutations. Results require clinical correlation.
References: AAN Ataxia Guidelines, 2023; Neurology, Lynch DR, 2022.
